Two Cases of Loss of Consciousness After Long-Term Memantine Treatment

Journal of the American Medical Directors Association

Volumn 14, Issue 5, 2013, Pages 375-376

  Savić, Aleksandar ^a,b   Mimica, Ninoslav ^a,b  

^a Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Alzheimer's disease; Loss of consciousness; Memantine; Neuropharmacology

Indexed keywords

ATORVASTATIN; BISOPROLOL; FLUVOXAMINE; HALOPERIDOL; MEMANTINE; PAROXETINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MUSCLE HYPOTONIA; TACHYCARDIA; UNCONSCIOUSNESS;

EID: 84876798002     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.01.010     Document Type: Article

References (14)

1. Thomas S.J., Grossberg G.T. Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009, 4:367-377.
2. Kavirajan H. Memantine: A comprehensive review of safety and efficacy. Expert Opin Drug Saf 2009, 8:89-109.
3. Jones R.W. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2010, 5:547-553.
4. Ebixa (memantinum) [package insert] 2009, H. Lundbeck A/S, Zagreb, Croatia.
5. Peltz G., Pacific D.M., Noviasky J.A., et al. Seizures associated with memantine use. Am J Health Syst Pharm 2005, 62:420-421.
6. Gallini A., Sommet A., Montastruc J.L. the French PharmacoVigilance Network. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf 2008, 17:877-881.
7. Sinforiani E., Pasotti C., Chiapella L., et al. Memantine in Alzheimer's disease: Experience in an Alzheimer's disease assessment unit. Aging Clin Exp Res 2012, 24:193-196.
8. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
9. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987, 10:299-302.
10. Kim S.H., Price M.T., Olney J.W., et al. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by gabaergic and α-2adrenergic agonists. Mol Psychiatry 1999, 4:344-352.
11. Farber N.B., Kim S.H., Dikranian K., et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002, 7:32-43.
12. Huey E.D., Dustin I.H., Overman G.P., et al. Development of subtle psychotic symptoms with memantine: a case report. J Clin Psychiatry 2005, 66:658-659.
13. Molinaro G., Battaglia G., Riozzi B., et al. Memantine treatment reduces the expression of the K(+)/Cl(-) cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA(A) receptor activation in mice. Brain Res 2009, 1265:75-79.
14. Creeley C.E., Wozniak D.F., Nardi A., et al. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 2008, 29:153-167.